DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment



MRI Homepage

New study highlights gender disparity in radiology Fewer female radiologists are publishing research

World's first 10.5-Tesla human MR scan performed at University of Minnesota A 110-ton magnet with a world of potential

New brain MR technique improves brain imaging for restless children Fewer motion and pulsation artifacts

Availity announces debut of pre-clearance service at HIMSS Confirms imaging authorization in minutes and ensures patient payments prior to visit

Lisa Hazen ARRT appoints new Nuclear Medicine Technology (NMT) Relationship Manager

Radiology firm sues MR service provider for more than $68,000 in unpaid services Alleges breach of contract for failure to pay for services rendered

Elekta partners with Memorial Sloan Kettering for cancer research on MR-linac Will test MR-linac in treating tumors in nine parts of the body

New 3T MR from Philips cuts scan time in half Ingenia Elition 3T was unveiled at ECR and uses AI to enhance workflow

Radiologists configure MR to find bone and brain metastases in 7 minutes Increases efficiency by roughly 30 percent

Study of the 2016 Summer Olympic Games sheds light on imaging utilization rates May help plan imaging services for future events

ACR responds to European PRAC recommendations on linear gadolinium agents

by Thomas Dworetzky , Contributing Reporter
The American College of Radiology has come out in disagreement with the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency, over its recommendations concerning linear gadolinium-based contrast agents (GBCAs).

The European group raised the alarm concerning the potential risk of gadolinium accumulation in humans, recommending “regulatory actions, including suspension for some marketing authorizations.”

Story Continues Below Advertisement

The (#1 Resource) for Medical Imaging and Peripherals. Call 1-949-273-8000

As a Master Distributor for major brands Barco, Philips, and Sony, we offer custom imaging solutions. With our renowned OEM Solutions and Service/Repair Center, Ampronix is a one-stop shop for HD Medical LCD Displays--Printers--Recorders--4K Cameras

The ACR advised that, “although intracranial gadolinium retention following intravenous GBCA administration has only recently been reported, it has been known for over 10 years that some gadolinium chelates are not completely stable in vivo.”

Based on its review of the findings, the group advised that, “fortunately, there is indisputable evidence that the amount of gadolinium deposited in tissues after a single GBCA dose is incredibly small, and is detectable using only the most sensitive of medical and scientific instrumentation,” — adding that, “although gadolinium accumulation appears to be dose-dependent, there remains no evidence of cellular toxicity, nor is there credible evidence of neurologic sequelae after over 300 million worldwide human doses.”

The PRAC review had found evidence of brain deposits of the agent in “small amounts” after MR body scans “but no signs of harm.”

In its March 10th announcement PRAC advised that the specific agents included:

  • Gadobenic acid, marketed under the trade name MultiHance by Bracco

  • Gadodiamide, sold under the trade name Omniscan by GE Healthcare

  • Gadopentetic acid, marketed as Magnevist by Bayer HealthCare Pharmaceuticals

  • Gadoversetamide, sold as Optimark by Guerbet

Guerbet “concurred” with the PRAC gadolinium recommendations, and in a March 31 statement announced that it had proactively requested a labeling change in the U.S. to Optimark (gadoversetamide) injection, which had been approved by the FDA in August, 2016.

“This change is included in the Pharmacokinetics section (12.3) of the Prescribing Information and notes: Increased signal intensity on non-contrast T1-weighted images within the brain, mainly the globus pallidus and the dentate nucleus, has been observed after multiple administrations of linear (ionic and nonionic) gadolinium-based contrast agents due to gadolinium deposition,” stated the company.

"Guerbet proactively sought this labeling change to ensure that prescribers and patients have all the relevant information clearly available regarding linear GBCAs," said Massimo Carrara, general manager, Guerbet U.S.
  Pages: 1 - 2 >>

MRI Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.